Results 51 to 60 of about 2,457 (145)
ABSTRACT Background The currently high pertussis‐related morbidity and mortality among infants has led to increased international attention for pertussis vaccination during pregnancy. We studied the safety of maternal pertussis vaccination in the Netherlands with respect to neonatal health. Methods Data from the cohort the Dutch Pregnancy Drug Register
Petra J. Woestenberg +7 more
wiley +1 more source
ABSTRACT Outer membrane vesicles (OMVs) are nanosized vesicles naturally secreted by Gram‐negative bacteria and represent a promising platform for vaccine development. OMVs possess inherent immunostimulatory properties due to the presence of pathogen‐associated molecular patterns (PAMPs), providing self‐adjuvanting capabilities and the ability to ...
Asja Garling +4 more
wiley +1 more source
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller +13 more
wiley +1 more source
Neonatal Immunity to Bordetella pertussis Infection and Current Prevention Strategies
Bordetella pertussis is the bacterial agent of whooping cough, an infectious disease that is reemerging despite high vaccine coverage. Newborn children are the most affected, not only because they are too young to be vaccinated but also due to qualitative and quantitative differences in their immune system, which makes them more susceptible to ...
Carolina Argondizo-Correia +3 more
wiley +1 more source
The authors demonstrate that current aP vaccines induce IL‐10‐secreting CD4+ and CD8+ Treg cells that suppress IL‐17‐secreting respiratory tissue‐resident memory (TRM) cells, and thereby fail to prevent nasal infection with B. pertussis. Blocking IL‐10R in vivo or adding a novel adjuvant LP‐GMP and intranasal delivery reverses suppression and enhances ...
Caitlín Ní Chasaide +11 more
wiley +1 more source
Bacterial Outer Membrane Vesicles: From Physics to Clinical
A review of an introduction to the mechanisms of formation of OMVs, their action on bacteria and relationship to disease, vaccines, biomonitoring, drug delivery and regenerative medicine in the clinic. ABSTRACT Bacterial outer membrane vesicles (OMVs) are nanoscale vesicular structures naturally produced by Gram‐negative bacteria during growth.
Jun Zhou +7 more
wiley +1 more source
Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis
Recent reemergence of pertussis (whooping cough) in highly vaccinated populations and rapid expansion of Bordetella pertussis strains lacking pertactin (PRN), a common acellular vaccine antigen, have raised the specter of vaccine-driven evolution and ...
Longhuan Ma +3 more
doaj +1 more source
Lonidamine, a Novel Modulator for the BvgAS System of Bordetella Species
ABSTRACT The Gram‐negative bacteria Bordetella pertussis, B. parapertussis, and B. bronchiseptica cause respiratory diseases in various mammals. They share the BvgAS two‐component system, which regulates the phenotypic conversion between the virulent Bvg+ and avirulent Bvg– phases.
Natsuko Ota +7 more
wiley +1 more source
Structure of Bordetella pertussis virulence factor P.69 pertactin
A new generation of whooping-cough vaccines contain P.69 pertactin, a surface-exposed domain of an outer membrane protein expressed by the virulent bacterium Bordetella pertussis.
Paul Emsley +12 more
core +1 more source
New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates
Evolution of Bordetella pertussis is driven by natural and vaccine pressures. Isolates circulating in regions with high vaccination coverage present multiple allelic and antigenic variations as compared to isolates collected before introduction of ...
Valérie Bouchez +4 more
doaj +1 more source

